Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
738.00
-6.50 (-0.87%)
Nov 22, 2024, 4:00 PM EST - Market closed
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.72B in the quarter ending September 30, 2024, with 10.65% growth. This brings the company's revenue in the last twelve months to $13.85B, up 5.72% year-over-year. In the year 2023, Regeneron Pharmaceuticals had annual revenue of $13.12B with 7.76% growth.
Revenue (ttm)
$13.85B
Revenue Growth
+5.72%
P/S Ratio
5.73
Revenue / Employee
$1,029,524
Employees
13,450
Market Cap
79.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CVS Health | 367.25B |
| McKesson | 330.19B |
| The Cigna Group | 229.75B |
| Elevance Health | 174.02B |
| HCA Healthcare | 69.62B |
| GSK | 41.97B |
| Medtronic | 33.00B |
| Gilead Sciences | 28.30B |
REGN News
- 4 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 4 days ago - Regeneron: The Biotech Stock To Buy Now - Seeking Alpha
- 9 days ago - Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewsWire
- 9 days ago - Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 10 days ago - Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - GlobeNewsWire
- 12 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 18 days ago - Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis - GlobeNewsWire
- 18 days ago - Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis - GlobeNewsWire